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PI 9  Proteinase inhibitor 9 
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Summary 
 
BK polyomavirus (BKV) is an important cause of graft loss in renal transplant recipients that 
continues to pose a significant challenge to clinicians due to its frequently unpredictable 
onset, persistence and the lack of effective antiviral agents or prevention strategies. This 
review covers our current understanding of epidemiology, viral transmission and disease 
progression, and treatment and prevention strategies that have been used to manage this 
disease. 
 
Introduction 
 
BKV is a small DNA virus first described in 1971 following the discovery of inclusion-
bearing cells in the urine of a Sudanese renal transplant recipient with ureteric stenosis1. With 
the widespread increase in potent immunosuppressive agents and enhanced viral surveillance 
practices, it has emerged as an important cause of graft loss in renal transplant recipients. 
This poses a significant challenge to clinicians due to an often brisk, aggressive onset, 
combined with the lack of effective antiviral agents or adequate prevention strategies. Despite 
an incidence of BKV nephropathy (BKVN) as high as 10% in renal transplant recipients, 
progress in our understanding, diagnosis and treatment of BKV has been laboured, and it 
remains a significant risk factor for potentially avoidable graft loss and increased mortality2,3 
(Figure 1). In this article, we review the current understanding of the virus, the pathogen:host 
interaction, the clinical impact of disease and potential areas for research and development. 
 
< Figure 1 > 
 Epidemiology 
 
BKV is ubiquitous with an estimated seroprevalence in the immunocompetent population of 
>80%4±9. Seroprevalence appears to decrease with age8,10. However, a large Dutch study of 
1050 blood donors showed no change in seropositivity towards BKV in older cohorts but 
there was a reduction in seroreactivity6, likely reflecting immunosenescence rather than a true 
reduction in prevalence. Intermittent viral shedding is found in 7%-20% of urine samples 
from healthy individuals10±14 with higher frequencies detected in immunosuppressed states 
and in pregnancy. Four BKV genotypes (I-IV) have been identified in the renal transplant 
population, although the full range of serotypes occurring in the general population has not 
been determined. Whilst genotype I is prevalent worldwide, genotype III occurs more 
frequently in Africa and genotype IV is prevalent throughout Asia and parts of Europe15. 
Furthermore, subtypes of each genotype also appear to have distinct distribution with IB 
found predominantly in American and European populations and IC in Asians16.  
 
Since the revolution of transplant immunosuppression presaged by the introduction of 
ciclosporin in 198317, there has been a global increase in post-transplant immunosuppression 
exposure. Standard immunosuppression now consists of a regime of tacrolimus and 
mycophenolate mofetil, following the landmark ELITE SYMPHONY study by Ekberg et al18 
in 2007, which showed improved rejection rates with tacrolimus compared to other agents; 
many centres also continue to use maintenance steroids. This has corresponded to dramatic 
increases in BKV detection rates. Rates of viraemia amongst renal transplant recipients vary 
widely in the reported literature, with prevalence ranging between 1.5%-33%, and peak 
incidence in the first year following transplantation19±21. The development of BKVN occurs 
in approximately 1-10% of cases19,22 and was historically associated with rates of graft loss 
approaching 50%2,3 However, the introduction of nationwide screening programmes in 2009, 
in many cases, allowed for early intervention and control of viraemia before the onset of 
florid interstitial disease23±25.  
 
Clinical course 
 
A range of possible transmission modalities have been suggested following detection of BKV 
in genital tissue and sperm suggesting sexual transmission26 and in maternal products and 
foetuses suggesting transplacental transmission27. However, BKV is thought to be mainly 
acquired via respiratory transmission. A Dutch study, performed in 1982, examined viral 
serology during hospitalisations for acute upper respiratory illnesses in 177 children and 
found that 8% demonstrated seroconversion to BKV28, suggesting a pathogenic association. 
Rarely, it has also been linked to otherwise unexplained cases of pneumonitis29±31, 
myopathy32, cystitis33,34, encephalitis29,35, bone marrow disorders36 and colonic ulceration37. 
In the vast majority of individuals, following a primary asymptomatic or mild respiratory 
infection in childhood, the virus is thought to remain clinically silent into adulthood, 
persisting predominantly in renal tubular and uroepithelial cells. However, intermittent 
asymptomatic viral shedding in the urine has been detected in healthy individuals10, 
particularly pregnant women12,38,39 and children13,38,40 and has not been associated with 
adverse outcomes (Figure 2). 
 
< Figure 2 > 
 
Clinically significant disease occurs almost exclusively in the immunosuppressed states seen 
in renal and haemopoeitic stem cell transplants (HSCT). The clinical features of infection 
range from asymptomatic viruria or viraemia to interstitial nephritis, ureteric strictures and 
haemorrhagic cystitis. Unlike the interstitial nephritis classically seen in renal transplant 
recipients, HSCT recipients typically develop haemorrhagic cystitis41,42, with reported 
incidences varying between 5%-70%41 and 10%-25% of patients42. This typically occurs in 
the first three months following transplantation and can lead to significant morbidity. It is 
unclear what leads to the development of these distinct phenotypes, although they may 
simply represent polar ends of a disease spectrum. It is possible that interstitial nephritis is 
under-recognised as a cause of renal dysfunction following HSCT, due to potentially culpable 
complex co-morbidities and reduced likelihood of proceeding to renal biopsy. Indeed, a case 
series of 124 HSCT recipients found that 16.4% developed BK viraemia. On multivariate 
analysis, this was shown to be an independent predictor of post transplantation renal 
dysfunction, with two patients developing dialysis-dependant, biopsy-proven, BKVN43.  
 
There is conflicting evidence of an association between BKV and malignancy, particularly 
urothelial malignancies, although BKV DNA has been detected in a range of tumour 
tissues44. A recent study detected human polyomavirus DNA by qPCR in 4% of the 689 
bladder urothelial cancer samples analysed, of which 23 were identified as BKV using 
genetic sequencing45. However, this finding is highly variable between different studies46 and 
may reflect a predisposition for viral uptake into tumour cells, rather than a causative 
mechanism. In favour of an oncogenic association, however, the BKV genome encodes two 
oncoproteins, large T (LT) and small t (st) antigens, which interact with tumour suppressor 
genes leading to cell immortalisation and neoplastic change46. Early viral infection has been 
shown to be highly oncogenic in mouse models, leading to a wide range of tumour types44. 
Furthermore, in a recent case series of 55697 transplant recipients, of whom over 2000 had 
BKV infection, the risk of invasive bladder tumours was found to be 4.5-fold higher than in 
the general population and 1.7-fold higher compared to transplant recipients without prior BK 
infection47. 
 
The relationship between BKV and renal transplant rejection remains the biggest challenge in 
developing an effective management strategy. BK viraemia increases the rate of antibody 
mediated rejection by promoting the development of de novo donor-specific antibodies 
(DSAs), particularly class II antibodies (HR 2.55)48. However, acute cellular rejection occurs 
more commonly, with rates of approximately 10%-23%23,49. Recently, 2 large sequential 
biopsy series of 61 and 71 patients with BKVN reported that 50%-61.9% developed acute 
rejection following immunosuppression reduction, which correlated to a 3-6 fold increased 
risk of graft failure50,51. Moderate to severe chronic interstitial fibrosis and tubular atrophy 
was seen in 67%, which correlated with poorer long-term outcomes. In the study by 
Nankivell et al50, 74% of the rejection episodes were consistent with acute cellular rejection 
and only 5% were antibody mediated. Further compounding this problem, recipients who are 
highly sensitised and have had previous rejection episodes, including ABO- and HLA-
incompatible transplants, appear to be more prone to developing BKV-associated disease, 
likely as a consequence of higher overall level of immunosuppression exposure52,53. 
Unsurprisingly, this cohort is also most likely to develop rejection following 
immunosuppression reduction. Therefore, there is an important unmet need to reliably 
distinguish between these two diagnoses, as, at present, treatment of one invariably increases 
the risk of developing the other.  
 
Genomic organization  
 The key to managing BKV-associated diseases may lie in understanding the viral life cycle 
and structure in order to identify potential therapeutic targets. BKV is a member of the 
human polyomavirus subfamily of the Polyomaviridae, along with JC polyomavirus (JCV) 
and Merkel cell polyomavirus (MCV)54. Within its 45-50 nm virion, the BKV genome exists 
as a double-stranded, covalently-closed, circular DNA packaged using host cell H2A, H2B, 
H3 and H4 histone proteins. The resulting viral mini-chromosome may interact directly with 
the capsid to facilitate genome packaging, as proposed by the sub-nanometer-resolution 
structure of native BKV55. The ~ 5.2 kb genome is arranged into three functional regions: the 
regulatory, early and late regions. The regulatory region is a non-coding control region 
(NCCR) which contains the origin of DNA replication, along with promoters to drive the 
transcription of early and late viral genes. Differences in the NCCR distinguish the two forms 
of BKV genome, termed archetype and rearranged BKV. Archetype virus is thought to be the 
transmissible form which is able to establish persistent, asymptomatic infection. The 
rearranged variant contains deletions or duplications within the NCCR and is the form of 
BKV associated with disease56±58.  
 
< Figure 3> 
 
Transcript production from the early coding region gives rise to the early proteins LT and st 
antigens (Figure 3). LT antigen is an important regulatory protein for late viral gene 
expression, with an additional role in DNA replication due to its helicase activity59.  
Following DNA replication, the structural proteins VP1, VP2 and VP3, and the agnoprotein 
are expressed from the late coding region of the genome during the later stages of infection. 
VP1 is the major structural protein, creating the capsid structure through assembly of 360 
VP1 molecules arranged in pentameric form (Figure 4A). The VP2 and VP3 minor capsid 
proteins are located on the internal surface of the capsid, with one molecule of VP2 or VP3 
associated with each VP1 pentamer55. Whilst expressed late in infection, the agnoprotein 
does not form a structural component of the virus capsid, but rather serves to aid in release of 
infectious progeny virus from the infected cell60.  
 
< Figure 4 > 
 
Viral lifecycle 
 
The BKV lifecycle begins when VP1 mediates cell adsorption via the b-series ganglioside 
receptors, GT1b (Figure 4 B) and GD1b, thus facilitating viral entry into target cells61,62. The 
viral entry pathway has only been partially elucidated to date. Both caveolae-dependent and 
caveolae- and clathrin-independent pathways have been observed for BKV internalization 
into primary renal proximal tubule epithelial (RPTE) cells, which represent the natural site of 
infection63. Moriyama et al. observed co-localization of labelled BKV with caveolin-1 in 
RPTE cells, suggesting BKV internalization occurs via caveolin-mediated endocytosis63. 
However, more recent work has demonstrated that cell entry may involve a caveolin- and 
clathrin-independent endocytosis, as silencing either process did not affect BKV infection of 
RPTE cells64. Zhao et al., therefore, suggest BKV gains entry into RPTE cells via an 
unknown endocytic pathway. Due to discrepant observations regarding BKV entry, further 
investigation is required to define the internalization mode of the virus. Following entry, BKV 
is transported along microtubules and traffics through the endoplasmic reticulum (ER) 
between 8 and 16 hours post infection (Figure 5). The virus undergoes partial capsid 
uncoating within the ER and gains entry into the cytosol through the ER-associated 
degradation pathway61%.9LVWKHQLPSRUWHGLQWRWKHQXFOHXVE\LPSRUWLQĮȕZKLFKELQGV
to a nuclear localisation signal on VP2 and VP3. Once inside the nucleus, BKV begins early 
gene expression by 24 hours post-infection65. DNA replication follows the synthesis of 
regulatory proteins and is initiated when LT antigen facilitates the assembly of the replication 
complex. Late gene transcription ensues and progeny virions are formed within the nucleus 
once capsid proteins assemble around the newly synthesized genomes66. These virions are 
then released from the infected cell by an incompletely understood mechanism which may 
require active secretion of virions rather than passive lysis of the infected cell60,67. 
 
< Figure 5 > 
 
Risk factors 
 
The clinical presentation of disease is often characteristic of the type of transplant. However, 
the relationship with immunosuppression appears to be complex. Although incompatible 
renal transplants may have higher rates of BKV infection, the association with degree of 
immunosuppression appears to be organ-specific. For instance, a lower incidence of BKV 
viraemia is seen in liver transplant recipients typically treated with less immunosuppression 
than their renal counterparts22. In contrary, clinically significant BKV is rarely seen in cardiac 
and lung transplant recipients despite their exposure to relatively higher levels of 
immunosuppression. This suggests yet unidentified key elements of pathogenesis associated 
with organ-specific immunosuppression or inflammation. One possible explanation, unique 
to renal transplantation, is trauma to the urothelium, which harbours BKV, during kidney 
implantation and from ureteric stent placement. The introduction of routine ureteric stent 
insertion 20 years ago corresponded to the observed rise in BKV infections. Several large 
retrospective studies have suggested a 1.35-2-fold increase in BK viraemia in transplant cases 
with ureteric stents compared to those where a stent was not employed68±70. In addition, a 
recent retrospective study of 400 transplant recipients found no BK viraemia in 160 patients 
with early stent removal71. 
 
A variety of other risk factors for BKV disease have been reported (see Table 123,52,53,72±81). 
Broadly, they divide into factors associated with immunosuppression, tubular injury or 
immunity. These include age, gender, HLA mismatches, deceased donor transplants, duration 
of cold ischaemic time, body mass index and types of immunosuppressive drugs, which have 
all been variably reported as risk factors. One of the most convincing studies is a multi-centre 
UHWURVSHFWLYHVWXG\RIµPDWH¶NLGQH\WUDQVSODQWSDLUVZKLFK compared outcomes 
between kidneys from the same donor, thus eliminating confounding donor factors. This 
study included 1975 discordant pairs, where one kidney recipient developed BKV infection 
and the other did not. Age under 18 or over 60, male sex, HLA mismatch, acute rejection and 
depleting antibody agents at induction were associated with higher odds ratios of requiring 
BKV treatment. However, immunosuppression with sirolimus appeared to reduce this risk 
(OR 0.46; Table 1)75. Despite several large studies aiming to identify risk factors, studies in 
ethnically diverse populations are lacking and none have led to a validated method of disease 
prediction. 
 
Interestingly, there is emerging evidence that BKV in transplant recipients originates from 
the donor kidney74,82,83 Recent studies have shown a strong correlation between donor BKV 
seroreactivity and the incidence of recipient BK viraemia and nephropathy74,84. There are 
several possible explanations: this could simply reflect transmission of a significant BK viral 
load/reservoir within the kidney, or transmission of a more virulent, or previously 
unencountered, viral serotype. An association between genotypes and more refractory disease 
has previously been described in a small study looking at 19 graft nephrectomies from 
patients with BKVN. A higher incidence of genotype 1 (11 of 19) was identified as the cause 
of graft loss85, although it is unclear if this merely reflected geographical prevalence. In a 
more recent study, genotyping of BKV in 19 patients with biopsy proven BKVN 
demonstrated a range of virulent genotypes including IA/C (16%), IB (16%), II (16%) and IV 
(5%) but their correlation to clinical severity was not evaluated50. There is emerging evidence 
that some genotypes are associated with more severe disease. A study in Brazil by Varella et 
al found that genotype 1A was associated with associated with a 10-fold higher urine BK 
viral load, compared with genotype 1B186. Similarly, Schwarz et al found a higher proportion 
of genotype IV affecting 31.8% of their 22 patients with BKVN, compared to the baseline 
frequency of genotype IV of 20% in their study83. However, it is unclear if it is the virulence 
of the transmitted virus that is important, or simply a mismatch between the transmitted virus 
DQGYLUDOVHURW\SHVSUHYLRXVO\HQFRXQWHUHGE\WKHKRVWWKDWLPSDLUVWKHKRVW¶VDELOLW\WRPRXQW
a robust immune response87. 
 
Diagnostic challenges 
 
In the modern era, urine cytology is rarely performed due to its poor specificity. With 
increasing ease and availability of determination of the BK viral DNA quantitative value by 
polymerase chain reaction (qPCR), this has become the mainstay of BKV detection. 
However, a rise in serum BKV levels in the context of elevated serum creatinine is not 
specific for BKVN alone50,51,88. Renal biopsy therefore remains the gold standard for 
diagnosis. However, this is time consuming, invasive and user-dependent. Moreover, the 
diagnosis of BKVN is missed in up to a third of renal biopsies due to the focal nature of the 
infection and the tendency for early disease to involve the collecting tubules which lie deeper 
within the kidney89. Interpretation also frequently poses a challenge due to significant overlap 
with histological findings seen between viral cytopathic changes and acute cellular rejection 
(Figure 6). This is illustrated in a recent study which reported that two of three cases received 
empirical treatment for rejection prior to reaching a BKVN diagnosis49.  
 
Histological staging was initially defined by the University of Maryland staging system90 as 
three stages of inflammation and tubular injury, regardless of the degree of viral cytopathy. 
This has since been modified and revised, most recently by the American Society of 
Transplantation (AST) in 201791. The current classification now incorporates the degree of 
viral cytopathic changes, as well as the degree of interstitial fibrosis and tubular atrophy, 
which were found to be reliable predictors of graft survival.  
 
What is clear is that early diagnosis is critical; by the time an allograft has significant 
irreversible interstitial fibrosis and atrophy, the prognosis is extremely poor. Given the 
challenges discussed, there has been considerable interest in the development of novel 
biomarkers for screening and monitoring of BKVN. Studies of urinary chemokines, including 
CXCL9 and CXCL1092, have shown potential benefit and correlate with our own centre 
experience. Similarly, urine exosomal micro RNA signatures93, urine proteinase inhibitor 9 
(PI 9) mRNA94, cellular assays for IFN-gamma95 and plasma donor-derived cell free DNA96 
have all demonstrated the ability to differentiate between various immune-mediated causes of 
transplant dysfunction. Furthermore, developments in urine proteomic profiling from 
Pittsburgh show promise in differentiating BKVN from acute rejection97. However, at 
present, there is still no reliable non-invasive method of making this distinction. 
 
< Figure 6 > 
 
Treatment strategies 
 
Most units in the UK now adhere to a policy of post transplantation screening for BKV DNA, 
as recommended by the 2009 KDIGO guidelines98. This involves monthly screening for the 
first 3-6 months and then every 3 months until the end of the first year, and varies from the 
AST recommendations to screen at least every 3 months for 2 years, then annually for 5 
years99. A robust screening program has proven critical, as the mainstay of treatment is early 
reduction in immunosuppression if significant viraemia occurs (e.g. if viral load exceeds 
>10000 copies/ml)49. However, although there is clearly benefit with screening and early 
immunosuppression reduction, this is associated with increased risk of rejection episodes50. 
Therefore, there is a pressing need for more effective treatments.  
 
To date, the benefits of drug treatment have been shown only in small trials or limited by 
toxicity. Disappointingly, systematic reviews evaluating the addition of leflunomide, 
cidofovir, intravenous immunoglobulins (IVIg) or ciprofloxacin to standard 
immunosuppression reduction have shown no overall improvement in graft survival100. 
However, a vaccine targeted at both CMV and BKV has been developed by VaxiGen by 
incorporating 3 DNA plasmids and is currently under evaluation in a phase 1 clinical trial101.  
 
Leflunomide 
  
Leflunomide is an immunomodulatory drug which inhibits DNA synthesis102. It was 
developed and first licensed for treating inflammatory arthritides in 1998. In vitro studies 
have demonstrated activity against DNA viruses including cytomegalovirus (CMV) and BKV 
by interfering with virion assembly103. Due to its immunosuppressive effects, it was used in 
the treatment of BKV as a replacement for mycophenolate mofetil (MMF). Several small 
studies104,105 and a systematic review including two in vitro studies, two retrospective cohort 
studies and three prospective observational trials suggested benefit106. However, in a phase II 
open label randomised trial comparing treatment with the active metabolite of leflunomide 
(FK778) to reduction of immunosuppression alone in 46 patients with biopsy proven BKVN 
or sustained viraemia, no benefit was seen107. In addition, the use of leflunomide has been 
limited by a large number of side effects. These include diarrhoea, liver dysfunction, bone 
marrow suppression, skin changes including Stevens Johnson syndrome, interstitial 
pneumonitis and severe allergic reactions. 
 
Cidofovir 
 
Cidofovir is an intravenous phosphonate nucleotide analogue originally developed for use in 
CMV infection. It is a prodrug that is diphosphorylated into an active form and acts by 
competitively inhibiting viral DNA synthesis by cellular DNA polymerase alpha108. 
However, the mechanism of BKV inhibition is unclear because, unlike viruses with larger 
DNA genomes, polyomaviruses do not encode a viral DNA polymerase. Several small trials 
have showed either stabilization in renal function or no benefit at all, with no clear benefit 
demonstrated in any meta-analysis of BKV treatments. Its use has also been largely limited 
by significant nephrotoxicity resulting in proteinuria and renal failure. A retrospective study 
of 27 HSCT recipients following cidofovir treatment showed a mean increase in serum 
creatinine by 27% from a mean baseline creatinine of 67µM/L (range 30-115), with renal 
failure occurring in 40% (as defined by >50% rise in serum creatinine) and two patients 
developing severe renal failure (creatinine clearance <30ml/min)109. However, a small trial 
used low dose cidofovir in eight patients and showed improved tolerance of the drug and a 
reduction in graft loss, albeit in the context of concomitant immunosuppression reduction110.  
 
Brincidofovir (CMX001) 
 
Brincidofovir is an oral lipid ester prodrug of cidofovir which has demonstrated promising 
anti-viral action against several DNA viruses111±113. It acts in a similar way to cidofovir by 
competitively inhibiting viral DNA synthesis111. The lipid formulation allows for higher 
potency with intracellular release and dramatically reduced renal toxicity compared to the 
parent drug. In vitro it has been shown to have over a 100-fold increased potency compared 
to cidofovir in suppressing Variola virus114. 
 
Interest in brincidofovir has recently shifted towards its use in BKV disease. Initially trialled 
in CMV, the SUPPRESS phase III randomised, placebo-controlled trial evaluated its use in 
452 HSCT recipients and failed to reach the primary end-point of CMV clearance. This was 
likely due to interpretation of the GUXJ¶VVLGH-effect of diarrhoea as a manifestation of graft 
versus host disease (GVHD), resulting in an 8-fold increase in steroid use in the treatment 
arm which correlated to an increase in CMV events and termination of the trial113. Several 
case reports have supported its use in BKV infection, including a report in 2014 on 
experimental usage of brincidofovir in a young child with persistently elevated BK viral load 
and renal dysfunction after a live donor kidney transplant. After a 36-week treatment course, 
BK viral load levels declined, although remained detectable. Epstein Barr virus (EBV) 
became undetectable and renal function improved to baseline, remaining stable for a further 
two year follow up, with no serious drug related adverse effects observed115. In 2015, a 
further report showed stabilisation of renal function and resolution of viraemia in a HSCT 
recipient with biopsy proven BKVN116. Furthermore, a phase II trial using brincidofovir in 
HSCT noted an improvement in renal function, postulated to be driven by anti-BKV effects. 
As a result, the drug manufacturers, Chimerix are now focusing on phase II trials on 
brincidofovir for targeting BKV in renal transplant recipients.  
 
 
Fluoroquinolones 
 
Several fluoroquinolones including ciprofloxacin and levofloxacin have been trialled in both 
the prophylaxis and treatment of BKV infection. They are thought to exert an anti-viral action 
via inhibition of DNA helicase and inhibiting viral replication117.  However, a systematic 
review including 8 trials with a total of 1477 participants showed no benefit of 
fluoroquinolone prophylaxis in preventing BKVN118. 
 
Intravenous immunoglobulins (IVIg) 
 
Due to the high seroprevalence of BKV in the population, commercially available IVIg 
preparations contain high titres of BKV neutralizing antibodies. It also has established benefit 
in acute rejection, making it an attractive treatment option. In vitro, co-incubation of BKV 
with human cells treated with IVIg or human albumin solution demonstrated a 95%-98% 
inhibition of BKV DNA yield after a 7 day culture119.  However, the current evidence of 
clinical benefit for IVIg for BKVN treatment is poor. Whilst serum neutralisation may be 
effective, the lack of convincing in vivo benefit may reflect an inability of IVIg to pass into 
the tubules to act at the site of direct viral replication. The evidence of benefit comes from a 
small Canadian cohort study where IVIg treatment prevented graft loss in seven of eight 
patients with established BKVN, albeit confounded by concurrent immunosuppression 
reduction120. A retrospective cohort study of 50 patients with biopsy-proven BKVN 
compared the addition of IVIg to treatment with leflunomide, ciprofloxacin and intravenous 
cidofovir, with cessation of MMF and conversion of tacrolimus to ciclosporin. They found 
faster viral clearance in the IVIg group (11 vs 29 months) and more complete resolution of 
viraemia (33.3% vs 77.3%), although graft and patient survival were not statistically 
different121. Overall, adequately powered randomized controlled trials are required to 
determine the efficacy of IVIg in this context.  
 
Inhibitors of the mammalian target of rapamycin (mTORi) 
 
Several studies have shown that the cellular mTOR pathway is pivotal to early BKV 
replication. mTORC-1 kinase and Akt, key components of the translation pathway, have been 
shown to be activated early in polyomavirus infection by LT and st antigens 122. In vitro, the 
mTOR inhibitor sirolimus impaired BKV replication in renal tubular epithelial cells, with a 
similar inhibitory profile seen with the mTORC1 kinase inhibitor Torin 1, suggesting an 
mTOR-dependent replication pathway. Interestingly, the subsequent addition of tacrolimus 
resulted in reversal of the sirolimus effect, with activation of BKV replication. This 
interaction suggests a shared pathway further evidenced by knock down of the FK binding 
protein of Mr 12,000 (FKBP-12), which resulted in a similar reversal of the sirolimus 
effect123. This led the authors to conclude that FKBP-12 is a regulatory component in the 
BKV replication pathway. Sirolimus has also been shown to inhibit the mTOR-dependent 
proliferation of BKV-specific T cells, whilst lacking the inhibitory effect of BKV-specific T 
cell activation seen with calcineurin inhibitors in vitro124.  
 In clinical practice, the mTORi drugs sirolimus and everolimus have both been used in many 
transplant units in patients with BKV with reports of superior outcomes in small case series. 
Unfortunately, these findings have not been reproduced in larger studies. Similarly, U.S. 
registry data of 42838 patients showed no difference in outcomes post-BKV treatment 
between patients on sirolimus compared with ciclosporin or tacrolimus-based 
immunosuppression. However, the beneficial effect may have been attenuated by differences 
in treatment with ciclosporin and tacrolimus and by the short study period72. Data from other 
studies comparing everolimus and MMF have shown significantly higher incidence and 
levels of viraemia with MMF125,126. Moscarelli also noted nine cases of graft loss in the MMF 
group (n=238) compared to none in the everolimus group (n=58)126. In all these studies, the 
perceived success of mTORi is confounded by the difficulty in separating the reduction of 
immunosuppression from the benefit of mTOR inhibition. Nonetheless, in patients with high 
immunological risk, in whom absolute reduction of immunosuppression is undesirable, 
conversion to an mTORi may be an option; indeed, the benefit of switching from MMF to 
Everolimus in BKV infection is currently being assessed in a phase 4 clinical trial127. 
 
 
Adoptive cytotoxic cell transfer 
 
There has been considerable interest and research into the development and use of viral-
specific T cell transfer for the treatment of viral infections such as CMV and EBV in bone 
marrow transplant recipients128. Although production is labour intensive and expensive, the 
development of viral-specific T cells (VST) from allogeneic stem cell donor peripheral blood 
mononuclear cells has proven a promising and safe treatment option in HSCT complicated by 
viral disease. One study generated cytotoxic T lymphocytes (CTLs) that recognised 12 
immunogenic antigens from BKV, EBV, CMV, adenovirus and human herpes virus 6 which 
demonstrated in vivo clonal expansion and a 94% sustained viral response in 11 allogeneic 
bone marrow transplant recipients129. This study included seven patients with BKV viraemia; 
of these, six achieved remission, three of whom had severe haemorrhagic cystitis which 
significantly improved within 2-4 weeks of VST administration. The single treatment failure 
was found to have received a donor cell line lacking BKV reactivity. A further report 
documented the successful use of BKV-specific CTLs in a HSCT patient with haemorrhagic 
cystitis84. In solid organ transplant recipients, adoptive CTL therapy is hampered by the need 
for continuing immunosuppression. However, tacrolimus-resistant EBV-specific CTLs have 
been successfully generated131, providing a potential treatment option for patients with 
BKVN who have high immunological risk and are unsuitable for immunosuppression 
reduction. A phase 2 trial using CTLs for in 20 patients with refractory EBV is currently on-
going132. Further promising data in the area comes from a recent phase I clinical trial of 
CMV-specific CTLs showing an 84% improvement in symptoms in 20 patients with CMV 
end-organ disease who had failed first line therapy and showed no serious adverse events133. 
However, further clinical trials are warranted to determine their use in solid organ 
transplantation.  
 
Conclusion 
It is clear that BKV continues to pose a significant challenge in renal transplantation. There is 
much work required to determine why clinical disease occurs in some patients and to 
understand the significant variation in clinical manifestations of the disease. The viral and 
host factors determining disease outcome are of great interest. Furthermore, greater 
understanding of BKV immunity should allow for better risk stratification and, potentially, 
individual tailoring of immunosuppression.  For those in whom immunosuppression 
reduction is not possible, there is a very real need for robust, randomised controlled studies in 
the search for safe and effective therapies. 
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